Adipotide (FTPP)
Targeted pro-apoptotic peptide. Binds prohibitin (vascular marker enriched on adipose-tissue vasculature) and delivers a pro-apoptotic D(KLAKLAK)2 motif to selectively destroy the blood supply to fat tissue.
How it clearsHalf cleared in ~2h. Most (~96%) gone by ~10h.
Compare these compounds
Mechanism, evidence, legal path, cost — all side-by-side.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
MD Anderson 2004 + 2011 work in obese rhesus monkeys showed ~11% body-weight reduction over 4 weeks via selective adipose-vasculature destruction. Phase 1 human trial (Barnhart 2011, prostate cancer) showed acute renal toxicity that halted further dosing — the kidney also expresses prohibitin so the targeting is not adipose-exclusive in humans. Pharma development stalled at the renal-safety endpoint. Adipotide nonetheless appears in legacy peptide-clinic catalogs + PPW + Pep-Talk archives because the obesity-cohort interest never fully died. Stack catalogs it for awareness + harm-reduction context.
Phase 1 human trial documented renal toxicity (Barnhart 2011) that halted pharma development. The mechanism is not adipose-exclusive in humans — kidney prohibitin expression makes off-target toxicity inherent. GLP-1 agonists (semaglutide, tirzepatide, retatrutide) have superseded Adipotide for the weight-loss use case with vastly better safety profiles. Don't run this.
Upload your data to see how it relates to Adipotide.
Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.
Upload in /historyPer-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- DMechanistic / anecdotal
Adipotide (FTPP) — primary mechanism: targeted pro-apoptotic peptide. binds prohibitin (vascular marker enriched on adipose-tissue vasculature) and delivers a pro-apoptotic d(klaklak)2 motif to selectively destroy the blood supply to fat tissue.
2 supporting referencesVerified 13d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Research tool · halted at Phase 1 for renal toxicity · grey-market product is unverified
Pre-filled with this compound's published dose range: Mouse: 0.43 mg/kg · no human-validated dose · experimental — no human protocol
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
No field reports yet
Field reports are added as users share their real-world protocols.
Next visit & citations
Handoff & sources
Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.